Obesity and Antiphospholipid Syndrome: A Particular Challenge in Pregnancy
DOI:
https://doi.org/10.17140/OROJ-2-109Keywords:
Obesity; Pregnancy; Antiphospholipid syndrome; Endothelial dysfunctionAbstract
Obesity is associated with a broad spectrum of chronic diseases, as well as cardiovascular diseases, such as diabetes, dyslipidemia, insulin resistance and hyperglycemia. Obesity
during pregnancy is of major concern due to the well-known risk factors for both the mother
and the child. Complications in pregnancy include recurrent miscarriages, gestational diabetes, hypertensive disorders, thromboembolism, and stillbirth. Additionally, maternal obesity
seems to have long-term consequences for offspring, predisposing or “programming” them to
the development of metabolic disease in adulthood. Antiphospholipid syndrome (APS) is an
autoimmune disease and is characterized by the presence of antiphospholipid antibodies (anticardiolipin antibodies/ACLA, lupus antikoagulans/LA and ß2-glycoprotein) in the maternal
circulation. These antibodies are associated with arterial and/or venous thromboses and with
adverse obstetric outcomes such as recurrent fetal loss, Preeclampsia (PE), Intrauterine growth
restriction (IUGR) and Intrauterine fetal death (IUFD).
Obesity and APS are both chronic diseases with similar, even long-term consequences
for mother and child; a co-occurrence of obesity and APS in pregnancy worsens the situation;
the use of novel therapeutical tools should be therefore encouraged. A better understanding
of the complex interactions between endothelial dysfunction and obesity and APS should be
further investigated. Obese women with known APS should be counselled before conception
not only about potential obstetrical complications as well as the long-term consequences for the
off-spring, but also about these important life-style modifications. This review will provide an
overview of obesity and APS in pregnancy and will discuss endothelial dysfunction as mechanism for adverse obstetric outcome in these chronic diseases.
References
WHO Consultation. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World health Organ Tech Rep Ser. 2000; 894: i-253.
Gilmore J. Bodymass index and health. Health Rep (Statistics Canada, Catalogue 82-003). 1999; 11(1): 31-43.
Williams IL, Wheatcroft SB, Shah AM, Kearney MT. Obesi-ty, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord. 2002; 26(6): 754-764.
Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endo-thelial dysfunction and diabetes: roles of hyperglycemia, impai-red insulin signaling and obesity. Cell Tissue Res. 2009; 335(1): 165-189. doi: 10.1007/s00441-008-0685-6
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005 16-22; 365): 1415-28
Catenacci VA, Hill JO, Wyatt HR. The obesity epidemic. Clin Chest Med. 2009; 30(3): 415-444.
Hu G, Tuomilehto J, Silventoinen K, Barengo NC, Peltonen M, Jousilahti P. The effects of physical activity and body mass index on cardiovascular, cancer and all-cause mortality among 47 212 middle-aged Finnish men and women. Int J Obes (Lond). 2005; 29(8): 894-902. doi: 10.1038/sj.ijo.0802870
Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. Public Health Nutr. 2004; 7: 187-200. doi: 10.1079/PHN2003588
Robinson HE, O‘Connell CM, Joseph KS, McLeod NL. Ma-ternal outcomes in pregnancies complicated by obesity. Obstet Gynecol. 2005; 106: 1357-1364.
Mauricio MD, Aldasoro M, Ortega J, Vila JM. Endothelial dysfunction in morbid obesity. Curr Pharm Des. 2013; 19(32): 5718-5729. doi: 10.2174/1381612811319320007
Lashen H, Fear K, Sturdee DW. Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study. Hum Reprod. 2004; 19: 1644-1646. doi: 10.1093/humrep/deh277
Boots CE, Bernardi LA, Stephenson MD. Frequency of eu-ploid miscarriage is increased in obese women with recurrent early pregnancy loss. Fertil Steril. 2014; 102: 455-459. doi: 10.1016/j.fertnstert.2014.05.005
Bellver J, Rossal LP, Bosch E, et al. Obesity and the risk of spontaneous abortion after oocyte donation. Fertil Steril. 2003; 79: 1136-1140. doi: 10.1016/S0015-0282(03)00176-6
Weiss JL, Malone FD, Emig D, et al. FASTER Research Consortium. Obesity obstetric complications and cesarean deli-very rate-a population based screening study. Am J Obstet Gyne-col. 2004; 190: 1091-1097.
Sheiner E, Levy A, Menes TS, Silverberg D, Katz M, Mazor M. Maternal obesity as an independent risk factor for caesarean delivery. Paediatr Perinat Epidemiol. 2004; 18: 196-201. doi: 10.1111/j.1365-3016.2004.00557.x
Sacks DA, Chen W. Estimating fetal weight in the manage-ment of macrosomia. Obstet Gynecol Survey. 2000; 55: 229-239.
Dietz PM, Callaghan WM, Morrow B, Cogswell ME. Popu-lation-based assessment of the risk of primary cesarean delivery due to excess pre-pregnancy weight among nulliparous women delivering term infants. Matern Child Health J. 2005; 9: 237- 244. doi: 10.1007/s10995-005-0003-9
Perlow JH, Morgan MA. Massive maternal obesity and peri-operative cesarean morbidity. Am J Obstet Gynecol. 1994; 170: 560-565.
Wall PD, Deucy EE, Glantz JC, Pressman EK. Vertical skin incisions and wound complications in the obese parturient. Obs-tet Gynecol. 2003; 102: 952-956.
Myles TD, Gooch J, Santolaya J. Obesity as an independent risk factor for infectious morbidity in patients who undergo ces-arean delivery. Obstet Gynecol. 2002; 100: 959-964
Fretts RC. Etiology and prevention of stillbirth. Am J Obstet Gynecol. 2005; 193: 1923-1935.
Cedergren MI. Maternal morbid obesity and the risk of ad-verse pregnancy outcome. Obstet Gynecol. 2004; 103: 219-224.
Davies GA, Maxwell C, McLeod L, et al. Society of Obste-tricians and Gynaecologists of Canada. Obesity in pregnancy. J Obstet Gynaecol Can. 2010; 32(2): 165-173.
Alfaradhi MZ, Ozanne SE. Developmental programming in response to maternal overnutrition. Frontiers in Genetics. 2011; 2(27). doi: 10.3389/fgene.2011.00027
Cedergren MI. Maternal morbid obesity and the risk of ad-verse pregnancy outcome. Obstet Gynecol. 2004; 103: 219-224.
Simmons R. Perinatal programming of obesity. Exp Geron-tol. 2005; 40: 863-866.
Gillman MW, Rifas-Siman SL, Berkey CS, Field AE, Col-ditz GA. Maternal gestational diabetes, and adolescent obesity. Pediatrics. 2003; 111: E221-E226.
Himmelmann A, Himmelmann K, Svensson A, Hans-son L. Glucose and insulin levels in young subjects with dif-ferent maternal histories of hypertension: the Hypertension in Pregnancy Offspring Study. J Int Med. 1997; 241: 19-22. doi: 10.1046/j.1365-2796.1997.66890000.x
Catalano PM, Ehrenberg HM. The short- and longterm im-plications of maternal obesity on the mother and her offspring. BJOG. 2006; 113(10): 1126-1133.
Edwards LE, Hellerstedt WL, Alton IR, Story M, Himes JH. Pregnancy complications and birth outcomes in obese and nor-mal-weight women: effects of gestational weight change. Obstet Gynecol. 1996; 87: 389-394.
Hotamisligil GS. Inflammation and metabolic disorders. Na-ture. 2006; 444 (7121): 860-867. doi: 10.1038/nature05485
Basu S, Haghiac M, Surace P, et al. Pregravid obesity associ-ates with increased maternal endotoxemia and metabolic inflam-mation. Obesity. 2011; 19(3): 476-482.
Madan JC, Davis JM, Craig WY, et al. Maternal obesity and markers of inflammation in pregnancy. Cytokine. 2009; 47 (1): 61-64. doi: 10.1016/j.cyto.2009.05.004
Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010; 2010: 802078.
Challier JC, Basu S, Bintein T, et al. Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta. Placenta. 2008; 29 (3): 274-281. doi: 10.1016/j.pla-centa.2007.12.010
X.Yan JF, Tong MJ, Zhu SP, Ford PW, Nathanielsz, Du M. Maternal obesity induces inflammation and adipogenesis in late gestation fetal sheep muscle. Diabetes. 2009; A85-A85.
Miyakis S, Lockshin MD, Atsumi T, et al. International con-sensus statement on an update of the classification criteria for definite antiphospholipide syndrome (APS). J Thromb Haemost. 2006; 4: 295-230. doi: 10.1111/j.1538-7836.2006.01753.x
Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5- mediated pathogenic mechanism in the antiphospholipid syn-drome: role in pregnancy losses and thrombosis. Lupus. 2010; 19(4): 460-469.
Girardi G, Berman J, Redecha P. Complement C5a recep-tors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003; 112: 1644-1654.
Holers VM, Girardi G, Mo L. Complement C3 activation is required antiphospholipid antibody induced fetal loss. J Exp Med. 2002; 195: 211-220. doi: 10.1084/jem.200116116
Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Bet-terle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol. 1993; 151(3): 1562-1570.
Salmon JE, Girardi G. The role of complement in the an-tiphospholipid syndrome. Curr Dir Autoimmun. 2004; 7: 133- 148.
Gary T, Belaj K, Bruckenberger R, et al. Primary antiphos-pholipid antibody syndrome-one further aspect of thrombophilia in overweight and obese patients with venous thromboembo-lism. Obesity (Silver Spring). 2013; 21(9).
Caldas CA, da Mota LM, de Carvalho JF. Obesity in primary antiphospholipid syndrome is associated with worse outcome. Joint Bone Spine. 2011; 78(3): 324-325.
Schiffrin EL. A critical review of the role of endothelial fac-tors in the pathogenesis of hypertension. J Cardiovasc Pharma-col. 2001; 38 (Suppl 2): S3-S6.
Garg UC, Hassid A. Nitric-oxid-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989; 83: 1774-1777. doi: 10.1172/JCI114081
Radomski MW, Palmer RM, Moncada S. Endogenous ni-tric oxide inhibits human platelet adhesion to vascular endo-thelium. Lancet. 1987; 2: 1057-1058. doi: 10.1016/S0140- 6736(87)91481-4
Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol. 2008; 103(56): 398-406. doi: 10.1007/s00395-008-0733-0
Palmer RH, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Com-mun. 1988;153(3): 1251-1256.
Iglarz M, Clozel M. Mechanisms of ET-1 induced endothe-lial dysfunction. J Cardiovasc Pharmacol. 2007; 50: 621-628.
Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vaso-constriction induced by acetylcholin in atheroslerotic coronary arteries. N Engl J Med. 1986; 315: 1046-1051.
Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004; 15: 1983-1992.
Amiri F, Virdis A, Neves MF, et al. Endothelium-restricted over-expression of human endothelin-1 causes vascular remode-ling and endothelial dysfunction. Circulation. 2004; 110: 2233- 2240.
Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stim-ulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem. 2001; 276(32): 30392-30398.
Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural acti-vation and vasodilation in normal humans. J Clin Invest. 1991; 87(6): 2246-2252.
Tack CJ, Schefman AE, Willems JL, Thien T, Lutterman JA, Smits P. Direct vasodilator effects of physiological hyperinsulin-aemia in human skeletal muscle. Eur J Clin Invest. 1996; 26(9): 772-778.
Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lan-cet. 1993; 342(8873): 707-709.
Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal re-lationships between insulin resistance and endothelial dysfunc-tion: molecular and pathophysiological mechanisms. Circula-tion. 2006; 113(15): 1888-904.
Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006; 55(5): 1436-1442. doi: 10.2337/db05-1373
Reyes-Soffer G, Holleran S, Di Tullio MR, et al. Endothe-lial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism. 2010; 59(9): 1365-1371.
Cooke JP. Asymmetrical Dimetyhlarginine. The Über-Marker? Circulation. 2004; 109: 1813-1819.
Surdacki A, Martens-Lobenhoffer J, Wloch A, et al. Elevated plasma asymmetric dimethyl-L-arginine levels are linked to en-dothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis. Rheum. 2007; 56: 809-819. doi: 10.1002/art.22424
Miyazaki P, Leone P, Calver A, et al. Endogenous nitric ox-ide synthase inhibitor: a novel marker of atherosclerosis. Cir-culation. 1999; 99: 1141-1146. doi: 10.1161/01.CIR.99.9.1141
Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship be-tween insulin resistance and an endogenous nitric oxide syn-thase inhibitor. JAMA. 2002; 287: 1420-1426. doi: 10.1001/ jama.287.11.1420
Boger RH, Bode-Borger SM, Szuba A, et al. Asymmetric dimethyl-arginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterinemia. Circulation. 1998; 98: 1842-1847.
Lundmann P, Erikson MJ, Stuhlinger M, et al. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001; 38: 111- 116. doi: 10.1016/S0735-1097(01)01318-3
McDermott JR. Studies on the catabolism of NG-methylargi-nine, NG, N’G-dimetyhlarginine and NG.NG-dimethylarginine. Biochem J. 1976; 154: 179-184.
Murray-Rust J, Leiper J, McAlister M, et al. Structural in-sights into the hydrolysis of cellular nitric oxide synthase inhibi-tors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol. 2001; 8(8): 679-683
Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregula-tion of dimethylarginine dimethylaminohydrolase. Circulation. 1999; 99(24): 3092-3095. doi: 10.1161/01.CIR.99.24.3092
Fogarty RD, Abhary S, Javadiyan S, et al. Relationship be-tween DDAH gene variants and serum ADMA level in individu-als with type 1 diabetes. J Diabetes Complications. 2012; 26(3): 195-198. doi: 10.1016/j.jdiacomp.2012.03.022
Turiel M, Atzeni F, Tomasoni L, et al. Non invasive assess-ment of coronary flow reserve and ADMA levels: A case-control study of early rheumatoid arthritis patients. Rheumatology (Ox-ford). 2009, 48, 834-839. doi: 10.1093/rheumatology/kep082
Sandoo A, Dimitroulas T, van Zanten V, et al. Lack of associ-ation between asymmetric dimethylarginine and in vivo micro-vascular or macrovascular endothelial function in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2012; 30: 388-396.
Atzeni F, Sarzi-Puttini P, Sitia S, et al. Coronary flow reserve and asymmetric dimethylarginine levels: New measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J. Rheumatol. 2011; 38: 1661-1664. doi: 10.3899/jrhe-um.100893
Sari I, Kebapcilar L, Alacacioglu A, et al. Increased levels of asymmetric dimethylarginine (ADMA) in patients with an-kylosing spondylitis. Intern. Med. 2009; 48: 1363-1368. doi: 10.2169/internalmedicine.48.2193
Kemény-Beke Á, Gesztelyi R, Bodnár N, et al. Increased production of asymmetric dimethylarginine (ADMA) in ankylo-sing spondylitis: Association with other clinical and laboratory parameters. Joint Bone Spine. 2011; 78: 184-187.
Kiani AN, Mahoney JA, Petri M. Asymmetric dimethylargi-nine is a marker of poor prognosis and coronary calcium in sys-temic lupus erythematosus. J Rheumatol. 2007; 34: 1502-1505.
Bultink EM, Teerlink T, Heijst JA, Dijkmans BA, Voskuyl AE. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and org-an damage in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005; 64: 1362-1365. doi: 10.1136/ard.2005.036137
Elmageed AM, Ahmed IK, Saleh BI, Ali SR. Exploring di-sease activity and cardiovascular events by raised serum asym-metric dimethyl arginine among systemic lupus erythematosus patients. Egypt J Immunol. 2001; 18: 43-49.
Fickling SA, Williams D, Vallance P, Nussey SS, Whitley GS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthesis in normal pregnancy and preeclampsia. Lancet. 1993; 342: 242-243.
Holden DP, Fickling SA, Whitley GS, et al. Plasma concen-trations of asymmetric dimethylarginine, a natural inhibitor of nitric oxid synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol. 1998; 178: 551-556. doi: 10.1016/S0002- 9378(98)70437-5
Petterson A, Hedner T, Milsom I. Increased circulating con-centrations of asymmetric dimethyl arginine (ADMA), an en-dogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand. 1998; 77: 808-813.
Savvidou MD, Hingorani AD, Tsikas D, et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently devel-op preeclampsia. Lancet. 2003; 361: 1511-1517. doi: 10.1016/ S0140-6736(03)13177-7
Cooke JP. NO and angiogenesis. Atheroscel Suppl. 2003; 4: 53-60.
Di Simone N, Di Nicuolo F, D’Ippolito S, et al. Antiphos-pholipid antibodies affect human endometrial angiogenesis. Biol reprod. 2010; 83: 212-219. doi: 10.1095/biolreprod.110.083410
Charakida M, Besler C, Batuca JR, et al. Vascular abnormal-ities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA. 2009; 302: 1210-1217. doi: 10.1001/jama.2009.1346
Ames PR, Batuca JR, Ciampa A, Iannaccone L, Delgado Alves J. Clinical relevance of nitric oxide metabolites and nitra-tive stress in thrombotic primary antiphospholipid syndrome. J Rheumatol. 2010; 37: 2523-2530. doi: 10.3899/jrheum.100494
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411-415. doi: 10.1038/332411a0
Best PJ, McKenna CJ, Hasdai D, et al. Chronic endothe-lin receptorantagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation. 1999; 99: 1747-1175
Oliver FJ, de la Rubia G, Feener EP, et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem. 1991; 266: 23251-23256.
Andronico G, Mangano M, Ferrara L, et al, Cerasola G. In vivo relationship between insulin and endothelin role of insulin-resistance. J Hum Hypertens. 1997; 11: 63-66.
Schneider JG, Tilly N, Hierl T, et al. Elevated plasma endo-thelin-1 levels in diabetes mellitus. Am J Hypertens. 2002; 15: 967-972.
Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP. Enhanced expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol. 2001; 280: R1388-R1392.
Deng LY, Day R, Schiffrin EL. Localization of sites of en-hanced expression of endothelin-1 in the kidney of DOCA-salt hypertensive rats. J Am Soc Nephrol. 1996; 7: 1158-1164.
Kassab S, Miller MT, Novak J, Reckelhoff J, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hyper-tension. 1998; 31: 397-402. doi: 10.1161/01.HYP.31.1.397
Schiffrin EL. Endothelin: a potential role in hypertension and vascular hypertrophy. Hypertension. 1995; 25: 1135-1143.
Weil BR, Westby CM, Van Guilder GP, Greiner JJ, Stauffer BL, DeSouza CA. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol. 2011; 301(3): H689-H695.
Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T. Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol. 2003; 35(6): 826-837.
Ou M, Dang Y, Mazzuca MQ, Basile R, Khalil RA. Adaptive regulation of endothelin receptor type-A and type-B in vascular smooth muscle cells during pregnancy in rats. J Cell Physiol. 2014; 229: 489-501.
Murdaca G, Colombo BA, Cagnati P, Gulli R, Spanò F, Puppo F. Endothelial Dysfunction in rheumatic autoimmune diseases. Atherosclerosis. 2012; 224: 309-317.
Filep G, Bodolay E, Sipka S, Gyimesi E, Csipo I, Szegedi G. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation. 1995; 92: 2969-2974. doi: 10.1161/01.CIR.92.10.2969
Yamada K, Miyauchi T, Suzuki N, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol. 1992; 19: 1566.
Lima J, Fonollosa V, Fernandez-Cortijo J, et al. Platelet activation, endothelial cell dysfunction in the absence of anti-cardiolipin antibodies in systemic sclerosis. J Rheumatol. 1991; 18: 1833-1836.
Hashimoto Y, Ziff M, Hurd ER. Increased endothelial cell adherence, aggregation, and superoxide generation by neutro-phils incubated in systemic lupus erythematosus and Felty’s syn-drome sera. Arthritis Rheum. 1982; 25: 1409-1418.
Ciołkiewicz M, Kuryliszyn-Moskal A, Klimiuk PA. Ana-lysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microva-scular changes in systemic lupus erythematosus patients. Clin Rheumatol. 2010; 29: 175-180.
Kuryliszyn-Moskal A, Klimiuk PA, Ciolkiewicz M, Siera-kowski S. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus. J Rheu-matol. 2008; 35: 1307-131360.
Atsumi T, Khamashta MA, Haworth RS, et al. Arterial di-sease and thrombosis in the antiphospholipid syndrome: a patho-genic role for Endothelin-1. Arthritis Rheum. 1998; 41: 800-807.
Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemoast. 2000; 84: 742-74662.
de Souza AW, Silva NP, de Carvalho JF, D‘Almeida V, No-guti MA, Sato EI. Impact of hypertension and hyperhomocystei-nemia on arterial thrombosis in primary antiphospholipid syndro-me. Lupus. 2007; 16: 782-787. doi: 10.1177/0961203307081847
Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab. 1990; 71: 1675-1677. doi: 10.1210/jcem-71-6-1675
Baksu B, Davas I, Baksu A, Akyol A. Gulbaba G. Plasma nitric oxide, endothelin-1 and urinary nitric oxide and cyclic gu-anosine monophosphate levels in hypertensive pregnant women. Int J Gynaecol Obstet. 2005; 90: 112-11742.
Nishikawa S, Miyamoto A, Yamamoto H, Ohshika H, Kudi R. The relationship between serum nitrate and endothelin-1 con-centrations in preeclampsia. Life Sci. 2000; 67: 1447-1454. doi: 10.1016/S0024-3205(00)00736-0
Maltaris T, Scalera F, Schlembach D, et al. Increased uterine arterial pressure and contractility of perfuses swine uterus after treatment with serum from preeclamptic women and endothe-lin-1. Clin Sci. 2005; 109: 209-215. doi: 10.1042/CS20040340
Schummers L, Hutcheon JA, Bodnar LM, Lieberman E, Himes KP. Risk of adverse pregnancy outcomes by prepregnan-cy body mass index: a population-based study to inform prep-regnancy weight loss counseling. Obstet Gynecol. 2015; 125(1): 133-143.
Segovia SA, Vickers MH, Gray C, Reynolds CM. Maternal obesity, inflammation, and development programming. Biomed Res Int. 2014; 2014: 418975. doi: 10.1155/2014/418975
Alijotas-Reig J. Treatment of refractory obstetric antiphos-pholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus. 2013; 22: 6-17
Sawhney N, Patel MK, Schachter M, Hughes AD. Inhibiti-on of proliferation by heparin and expression of p53 in cultured human vascular smooth muscle cells. J Hum Hypertens. 1997; 11: 611-614.
Kohno M, Yokokawa K, Yasunari K, et al. Heparin inhibits human coronary artery smooth muscle cell migration. Metabo-lism. 1998; 47: 1065-1069. doi: 1016/S0026-0495(98)90279-7
Dilley RJ, Nataatmadja MI. Heparin inhibits mesenteric vascular hypertrophy in angiotensin II-infusion hypertension in rats. Cardiovasc Res. 1998; 38: 247-255.
Ragazzi E, Chinellato A. Heparin: Pharmacological poten-tials from atherosclerosis to asthma. Gen Pharmacol. 1995; 26: 697-701.
Shulman AG. Heparin and atherosclerosis: An investigative report on the treatment of atherosclerosis. Biomed Pharmaco-ther. 1990; 44: 303-306.
Engelberg H. Heparin and atherosclerosis. A review of old and recent findings. Am Heart J. 1980; 99: 359-372.
Vasdev S, Prabhakaran V, Sampson CA. Heparin lowers blood pressure and vascular calcium uptake in hypertensive rats. Scand J Clin Lab Invest. 1991; 51: 321-327.
Susic D, Mandal AK, Kentera D. Heparin lowers the blood pressure in hypertensive rats. Hypertension. 1982; 4: 681-685.
Imai T.Heparin has an inhibitory effect on endothelin-1 synthesis and release by endothelial cells. Hypertension. 1993; 21: 353-358.
Imai T, Hirata Y, Marumoand F. Heparin inhibits endothe-lin-1 and proto-oncogene c-fos gene expression in cultured bo-vine endothelial cells. J Cardiovasc Pharmacol. 1993; 22(Suppl 8): S49-S52.
Castellot JJ Jr. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem. 1982; 257: 11256-11260.
Yokokawa K. Heparin suppresses endothelin-1 peptide and mRNA expression in cultured endothelial cells of spontaneously hypertensive rats. J Am Soc Nephrol. 1994; 4: 1683-1689.
Yokokawa K. Effect of heparin on endothelin-1 production by cultured human endothelial cells. J Cardiovasc Pharmacol. 1993; 22(Suppl 8): S46-S48.
Kuwahara-Watanabe K, Hidai C, Ikeda H, et al. Heparin regulates transcription of endothelin-1 gene in endothelial cells. J Vasc. Res. 2005; 42: 183-189.
Agapitov A, Haynes WG. Role of endothelin in cardiovas-cular disease. JRAAS. 2002; 3: 1-15. doi: 10.3317/jraas.2002.001
Clouthier DE, Hosoda K, Richardson JA, et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development. 1998; 125: 813-824.
George EM, Granger JP. Endothelin: Key mediator o hy-pertension in preeclampsia. Am J Hypertens. 2001; 24: 964-969. doi: 10.1038/ajh.2011.99
Kingman M, Ruggiero R, Torres F. Ambrisentan, an endothelial receptor A-selective endothelin receptor an-tagonist, for the treatment of pulmonary arterial hyperten-sion. Expert Opin Pharmacother. 2009; 10: 1847-1858. doi: 10.1517/14656560903061275
Taniguchi T, Muramatsu I. Pharmacological knockout of endothelin ET (A) receptors. Life Sci. 2003; 74: 405-409. doi: 10.1016/j.lfs.2003.09.027
Paradis A, Zhang L. Role of endothelin in uteroplacen-tal circulation and fetal vascular function. Role of endothelin in uteroplacental circulation and fetal vascular function. 2013; 11: 594-605.
Spinelli FR, Di Franco M, Metere A, et al. Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis. Drug Dev Res. 2014; 75(Suppl 1): S67-S69. doi: 10.1002/ddr.21200
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Obesity Research (OR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
